![](https://netrf.org/wp-content/uploads/2019/06/NETRF-2018-Symposium-D2-00031350x230-300x197.jpg)
In Memory of Carol Branaman
Neuroendocrine cancer community faces loss. Carol Branaman, vice chair and former chair of NETRF, passes from neuroendocrine cancer.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
Neuroendocrine cancer community faces loss. Carol Branaman, vice chair and former chair of NETRF, passes from neuroendocrine cancer.
Latest in NET Cancer Research Neuroendocrine Tumor Research Foundation (NETRF) held its 11th Annual Research Symposium on May 2-3, 2019, in Cambridge, MA. More than
NETRF & Broad Institute Work to Fill Research Void The lack of publicly available, reliable NET cell lines is a barrier in neuroendocrine tumor research,
Mark A. Lewis, MD, Director of Gastrointestinal Oncology, Intermountain Healthcare, Utah, has joined the Board of Directors for the Neuroendocrine Tumor Research Foundation. Dr. Lewis,
New grants to explore CAR-T, PRRT, a vaccine for NETs and other innovative approaches.
Early Research on Targeting Single Cancer Cells to Prevent Metastasis Despite the effectiveness of Peptide Receptor Radionuclide Therapy (PRRT) to prolong survival of those with
The Neuroendocrine Tumor Research Foundation (NETRF) gratefully received a $35,000 donation for NET research from the CarGurus Charitable Giving Fund. NETRF was nominated by a
Antibody-drug conjugate aims to combine the benefits of targeted therapy and chemotherapy Renata Jaskula-Sztul, PhD, Assistant Professor of Surgical Oncology at the University of Alabama
We are proud to welcome Brendan P. Foley, Jr. as the newest member of the NET Research Foundation Board of Directors. Brendan has been elected
NETRF has launched a $10 million fundraising campaign, the largest of its kind in our history. Every gift we receive will be MATCHED, doubling our